Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center, Executive Director, Global Diabetes Program, Parkland Health and Hospital System

Endocrinology

Luigi Meneghini works in the field of Endocrinology. He researched medicine at Emory University School of Medicine. Emory University School of Medicine is ranked 23/42 in Research/PrimaryCare. He has 25 awards "Whos Who in America", "The Leading Physicians of the World", "Top Doctors:South Florida", "CMS Meaningful Use Stage 1 Certification", "Cambridge Whos Who Registry of Healthcare Professionals", "Americas Top Physicians", "Castle Connolly Top Doctor", "Who's Who Among Executives and Professionals", "South Florida Super Doctors", "Whos Who in Medicine and Healthcare", "Regional Castle Connolly Top Doctor", "Florida Super Doctors", "Americas Registry of Outstanding Professionals", "The Global Directory of Whos Who", "Best Doctors in America", "Honorary Citizen of Cartagena de Indias", "Floridas Best Doctors", "Best Doctors", "Guide to Americas Top Physicians", "Dean's Scholarship for Executive Master's in Business Administration Program", "Valedictorian", "Physicians Recognition Award", "W. J. Hurst Award in Clinical Methods", "Bray Award for French Majors" and "Super Doctor". Luigi F. Meneghini, MD is a published doctor as well. He has 33 publications published. The latest was: Stepwise addition of prandial insulin. Dr. Luigi F. Meneghini is registered with Medicare and accepts Medicare payments.

Publications

---

• Stepwise addition of prandial insulin.
• Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir With insulin glargine in patients...
• The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Da...
• Bariatric intervention effective at reversing Type 2 Diabetes.
• Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 Diabetes mellitus inadequately controlled by once-daily insulin detemir and oral an...
• Insulin for intensifying Diabetes treatment.
• Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 Diabetes.
• Insulin degludec in type 1 Diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
• Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 Diabetes mellitus.
• Practical aspects and considerations when switching between continuous subcutaneous insulin infusion and multiple daily injections.
• Practical guidance to insulin management.
• 'Will I have to be on insulin for the rest of my life?': Introduction.
• Insulin detemir: A historical perspective on a modern basal insulin analogue.
• Anti-glycation and anti-albuminuric effects of GLY-230 in human Diabetes.
• Early insulin treatment in type 2 Diabetes: what are the pros?
• Perioperative management of Diabetes: translating evidence into practice.
• Basal-bolus therapy With insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial.
• Superior mesenteric artery syndrome in type 1 Diabetes masquerading as gastroparesis.
• Ethnic disparities in Diabetes care: myth or reality?
• Clarification of the similarities and differences among insulin analog preparations: response to Becker.
• Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 Diabetes: a subgroup analysis of the US PREDICTIVE 303 st...
• The Avandia debacle: methodology and practical importance of the findings.
• Appropriate advancement of type 2 Diabetes therapy.
• Continued use of an integrated meter With electronic logbook maintains improvements in glycemic control beyond a randomized, controlled trial.
• Pharmacotherapies for Diabetes management: an update for the practicing clinician.
• Why and how to use insulin therapy earlier in the management of type 2 Diabetes.
• Impact of bariatric surgery on type 2 Diabetes.
• Prevalence and associations of binge eating disorder in a multiethnic population with type 2 Diabetes.
• How good is your glucose control?
• Evaluation of metabolic control using a continuous subcutaneous glucose monitoring system in patients with type 1 Diabetes mellitus who achieved insulin independence a...
• Obesity, bariatric surgery and type 2 Diabetes--a systematic review.
• Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with Type 2...

Schools

---

• Emory University School Of Medicine

• University MiamiJackson Mem Mc

Conditions Treated

---

• Abnormal Thyroid
• Acromegaly and Gigantism
• Adrenal Insufficiency
• Calcium Metabolism Disorders
• View All

Doctors Specialties

---

• Endocrinology

Accepted Insurances

---

• Aetna HMO
• Choice Plus POS II
• Assurant Health
• AvMed
• Blue Card PPO
• Blue Choice
• Cigna HMO
• Cigna PPO
• Great West Healthcare-Cigna PPO
• LocalPlus
• Open Access Plus
• Commercial Insurance Company
• Coventry Health Care
• Emblem Health
• First Health (Coventry Health Care) PPO
• Golden Rule
• Guardian
• HealthPartners
• Choice Care PPO
• Preferred PPO
• Select HMO
• Medica
• Medicaid
• Medicare MCR
• PHCS Network PPO
• Mutual of Omaha
• MVP Health Care
• Neighborhood Health Plan
• Principal Life
• Tricare
• Choice Plus POS
• Navigate HMO
• Navigate POS
• Neighborhood Health Partnership
• Options PPO
• United Healthcare
• Worker's Compensation WC

Awards

---

• Who’s Who in America
• The Leading Physicians of the World
• Top Doctors:South Florida
• CMS Meaningful Use Stage 1 Certification
• Cambridge Who’s Who Registry of Healthcare Professionals
• America’s Top Physicians
• Castle Connolly Top Doctor
• Who's Who Among Executives and Professionals
• South Florida Super Doctors
• Who’s Who in Medicine and Healthcare
• Regional Castle Connolly Top Doctor
• Florida Super Doctors
• America’s Registry of Outstanding Professionals
• The Global Directory of Who’s Who
• Best Doctors in America
• Honorary Citizen of Cartagena de Indias
• Florida’s Best Doctors
• Best Doctors
• Guide to America’s Top Physicians
• Dean's Scholarship for Executive Master's in Business Administration Program
• Valedictorian
• Physician’s Recognition Award
• W. J. Hurst Award in Clinical Methods
• Bray Award for French Majors
• Super Doctor

Education

---

• Jackson Memorial Hospital - Jackson Health System
• University of Miami
• University of Miami School of Business
• Emory University School of Medicine
• Emory University

Hospital

---

• Parkland Health & Hospital System
• University of Texas Southwestern Medical Center

Drug Facts

---

NPI NUMBER		1245295831
NPPES Provider LastName		MENEGHINI
NPPES Provider FirstName		LUIGI
NPPES Provider ZIPCode		753907201
NPPES Provider State		TX
Specialty Description		Endocrinology
Total Claim Count		2359.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1245295831
Last Name Of The Provider	MENEGHINI
First Name Of The Provider	LUIGI
View All

Similar Doctors

---

	Dr. Robert E. Aden, MD This Doctor is OpenDoctor Recommended.
	Dr. Marco Danon, MD This Doctor is OpenDoctor Recommended.
	Dr. Raquel N. Faradji, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog